Physician profile
Tammy Webb
NPI 1720196074
$1,858.15
in general payments reported to CMS, 2019-2025
12 companies · $694 in 2025
The $694 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $192 · 2022: $241 · 2023: $365 · 2024: $366 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,425.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $448.34 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $321.27 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $288.22 | 2025 | Fanapt, Hetlioz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $270.67 | 2021-2023 | Xifaxan, Plenvu |
| Abbvie INC. | $114.77 | 2021-2025 | |
| Axsome Therapeutics, INC. | $105.74 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $101.58 | 2023 | Ingrezza |
| Madrigal Pharmaceuticals | $87.10 | 2024-2025 | Rezdiffra, Resmetirom |
| Otsuka America Pharmaceutical, INC. | $62.02 | 2025 | Rexulti |
| Alkermes, INC. | $31.22 | 2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $14.36 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $12.86 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.